Qiagen offers cervical screening in India

22 April 2009

Netherlands-based diagnostics firm Qiagen is to work with the Chittaranjan National Cancer Institute to establish the first  large-scale cervical cancer screening program for women in Kolkata,  India.

The Qiagencares Kolkata Project will use Qiagen's hybrid capture human  papillomavirus DNA testing technology to screen women for cancer-causing  types of HPV to identify those with, or at risk of, developing cervical  cancer. The project also includes educational campaigns to raise  awareness about HPV, cervical cancer, and other women's health issues.  The initiative will be conducted over five years and is expected to  reach 50,000 women.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight